These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30354399)

  • 61. Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease.
    Croteau D; Qin F; Chambers JM; Kallick E; Luptak I; Panagia M; Pimentel DR; Siwik DA; Colucci WS
    JACC Basic Transl Sci; 2020 Sep; 5(9):916-927. PubMed ID: 33015414
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes.
    Tobe SW; Poon S
    Circulation; 2020 Sep; 142(13):1246-1248. PubMed ID: 32986477
    [No Abstract]   [Full Text] [Related]  

  • 63. Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma.
    Andersen UØ; Terzic D; Wewer Albrechtsen NJ; Dall Mark P; Plomgaard P; Rehfeld JF; Gustafsson F; Goetze JP
    Endocr Connect; 2020 May; 9(5):438-444. PubMed ID: 32348960
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.
    Januzzi JL; Butler J; Sattar N; Xu J; Shaw W; Rosenthal N; Pfeifer M; Mahaffey KW; Neal B; Hansen MK
    Diabetes Care; 2021 Jan; 44(1):210-216. PubMed ID: 33158949
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Elevated plasma sRAGE and IGFBP7 in heart failure decrease after heart transplantation in association with haemodynamics.
    Ahmed A; Ahmed S; Arvidsson M; Bouzina H; Lundgren J; Rådegran G
    ESC Heart Fail; 2020 Oct; 7(5):2340-2353. PubMed ID: 32548968
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions.
    Cohen LP; Bellows BK
    JAMA Cardiol; 2023 Nov; 8(11):1048-1049. PubMed ID: 37755820
    [No Abstract]   [Full Text] [Related]  

  • 67. Neprilysin as a Biomarker: Challenges and Opportunities.
    Pavo N; Prausmüller S; Bartko PE; Goliasch G; Hülsmann M
    Card Fail Rev; 2020 Mar; 6():e23. PubMed ID: 32944293
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Importance of Lung Ultrasound and IGFBP7 (Insulin-like Growth Factor Binding Protein 7) Assessment in Diagnosing Patients with Heart Failure.
    Szyszkowska A; Olesiewicz T; Płońska-Korabiewska I; Tarasiuk E; Olesiewicz B; Knapp M; Śledziewski R; Sobkowicz B; Lisowska A
    J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673493
    [No Abstract]   [Full Text] [Related]  

  • 69. Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure.
    Chugh S; Ouzounian M; Lu Z; Mohamed S; Li W; Bousette N; Liu PP; Gramolini AO
    Proteomics; 2013 Aug; 13(15):2324-34. PubMed ID: 23713052
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease.
    Reddy YNV; Iyer SR; Scott CG; Rodeheffer RJ; Bailey K; Jenkins G; Batzler A; Redfield MM; Burnett JC; Pereira NL
    J Am Heart Assoc; 2019 Aug; 8(15):e012943. PubMed ID: 31345101
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Angiotensin receptor-neprilisyn inhibitors: Are their beneficial effects mediated through diastolic or systolic function improvement?
    Oikonomou E; Tsioufis C; Tousoulis D
    Hellenic J Cardiol; 2020; 61(6):419-420. PubMed ID: 33631345
    [No Abstract]   [Full Text] [Related]  

  • 72. Effects of combined therapy of valsartan and rosuvastatin on patients with atrial fibrillation.
    Hu WM; Shi ZH; Wu DY; Ye SY; Xiang YJ; Liu C; Chen JC; Zeng CL
    J Biol Regul Homeost Agents; 2020; 34(6):2215-2220. PubMed ID: 33185084
    [No Abstract]   [Full Text] [Related]  

  • 73. Fine-Tuning Risk Stratification in Heart Failure: Does It Improve Patient Care?
    Myhre PL; Omland T
    JACC Heart Fail; 2023 Jun; 11(6):675-677. PubMed ID: 37052547
    [No Abstract]   [Full Text] [Related]  

  • 74. Step by Step Toward Biomarker-Based Precision Medicine in Heart Failure.
    Bayes-Genis A; Núñez J
    Clin Chem; 2019 Oct; 65(10):1187-1189. PubMed ID: 31362933
    [No Abstract]   [Full Text] [Related]  

  • 75. Retraction Notice to: Insulin-like Growth Factor-binding Protein-7 (IGFBP7): A Promising Gene Therapeutic for Hepatocellular Carcinoma (HCC).
    Chen D; Siddiq A; Emdad L; Rajasekaran D; Gredler R; Shen XN; Santhekadur PK; Srivastava J; Robertson CL; Dmitriev I; Kashentseva EA; Curiel DT; Fisher PB; Sarkar D
    Mol Ther; 2023 Feb; 31(2):599. PubMed ID: 36587625
    [No Abstract]   [Full Text] [Related]  

  • 76. Is there an association between anxiety symptoms and valsartan treatment?
    Shad MU
    J Affect Disord; 2020 Jan; 261():111-112. PubMed ID: 31610311
    [No Abstract]   [Full Text] [Related]  

  • 77. Insulin-like growth factor binding protein-7 in heart failure: The challenge of moving from risk prediction to a biomarker-guided management.
    Panichella G; Tomasoni D; Aimo A
    Eur J Heart Fail; 2024 May; ():. PubMed ID: 38741028
    [No Abstract]   [Full Text] [Related]  

  • 78. Established and Emerging Roles of Biomarkers in Heart Failure.
    Ibrahim NE; Januzzi JL
    Circ Res; 2018 Aug; 123(5):614-629. PubMed ID: 30355136
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?
    Sarrias A; Bayes-Genis A
    Circulation; 2018 Aug; 138(6):551-553. PubMed ID: 30354612
    [No Abstract]   [Full Text] [Related]  

  • 80. Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease.
    James M; Manns B
    Circulation; 2018 Oct; 138(15):1515-1518. PubMed ID: 30354525
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.